profit from every $100 of sales.
$0$100
ENvue Medical
$0.24-6.85% today
-89.7% in 1 year
1-year low $0.121-year high $15.84
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What ENvue Medical sold, what it kept, and what it did with the cash.
Sales went from $752,000 in 2022 to $2.55 million in 2025, with -$18.2 million of profit last year.
SalesProfit
ENvue Medical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ENvue Medical | No profit yet | ||
 Ekso Bionics Holdings | No profit yet | ||
 Takara Bio | 130.9× · Very expensive | ||
 Mobia Medical | No profit yet | ||
 Shoulder Innovations | No profit yet |
AI analysis
An AI analyst reads ENvue Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 2 | 3 | 3 | |
| 0 | 2 | 2 | 0 | |
| -5 | -3 | -4 | -12 | |
| -5 | -4 | -4 | -11 | |
| -5 | -4 | -4 | -18 | |
| -422.40 | -233.20 | -137.30 | -26.69 | |
| 22.2% | 67.3% | 59.0% | 6.0% | |
| -666.5% | -150.5% | -140.0% | -459.7% | |
| -724.5% | -162.5% | -144.8% | -712.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6 | 7 | 4 | 41 |
| Cash | 3 | 3 | 1 | 4 |
| Total debt | 0 | 0 | 0 | 1 |
| Total liabilities | 3 | 3 | 3 | 8 |
| 3 | 4 | 1 | 33 | |
| 0 | 0 | 0 | 1 | |
| -120.8% | -70.2% | -380.9% | -26.7% | |
| -168.5% | -93.1% | -590.9% | -54.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -4 | -3 | -9 | |
| 0 | 0 | 0 | 0 | |
| -7 | -4 | -3 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 5 | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.0×
- 0.1×
- –
- –
- -4,215.9%
- -8,128.3%
- 0.0%
Profitability
- 6.0%
- -459.7%
- -712.3%
- -424.5%
- -32.4%
- -206.6%
- -39.2%
- -36.2%
- -34.1%
- 69.0%
Growth
- +50.3%
- –
- −274.4%
- –
- +194.3%
Financial health
- -0.3×
- 0.04
- 2.9%
- -39.4×
- 1.09
- 0.74
- 0.06
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 946
Top 12%of 867
What analysts expect
- Average price target
- $4.65
- Range
- $4.65 – $4.65
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -6.88 | – | – |
News
Higher feed costs present a new headwind for Cal-Maine Foods -- StoneXSeeking Alpha · Sep 4, 2026The newest story we have is from Sep 4, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
62Pass
Philip Fisher
39No pass
Peter Lynch
100Pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
22No pass
Questions about ENvue Medical
Is ENvue Medical a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ENvue Medical AI analysis
What does ENvue Medical do?
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. It is in Medical - Specialties.
Does ENvue Medical pay a dividend?
No. ENvue Medical does not pay a dividend at the moment; in 2025 it returned $5.00 million to shareholders by buying back its own shares.
Is ENvue Medical stock halal?
No. ENvue Medical does not pass our halal screen: its debt is 498% of its market value, at or above the 33% limit. How we check
How has ENvue Medical stock done over the past year?
Down 89.7% over the past twelve months, to $0.24. It traded between $0.12 and $15.84 and is 98.5% below its high.
Who are ENvue Medical's competitors?
The largest listed companies in the same industry are Ekso Bionics Holdings, Takara Bio, Mobia Medical and Shoulder Innovations. The peers table on this page compares their profit, growth and price with ENvue Medical's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.